Drugs.com - Clinical Trials

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

SAN CARLOS, Calif.--(BUSINESS WIRE) April 3, 2025 -- BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical...

Apr 8, 2025 - 04:55
 0
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
SAN CARLOS, Calif.--(BUSINESS WIRE) April 3, 2025 -- BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical...
Read More

Tags:

Previous Article

Samsung boosts profits as customers stockpile chips ahead of tariffs

Next Article

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Tri...

Related Posts

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Salarius Pharmaceuticals Announces Patient Enrollment t...

Feb 9, 2025  0

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Class CD5 CAR-T Cell Therapy, for T-Cell Lymphoma

March Biosciences Receives FDA Orphan Drug Designation ...

Feb 9, 2025  0

LimmaTech Awarded FDA Fast Track Designation for Vaccine Candidate Against Staphylococcus aureus

LimmaTech Awarded FDA Fast Track Designation for Vaccin...

Feb 9, 2025  0